Overview: Sugar Check Panel
Introduction: The Sugar Check Panel is a diagnostic tool designed to screen for diabetes using plasma samples. In India, diabetes affects ~77 million adults (second highest globally), with ~50 percent undiagnosed, higher in urban areas but rising in rural/low-SES due to lifestyle changes, poor diet, and limited screening. High morbidity from under-testing leading to delayed lifestyle/medical intervention, causing microvascular (retinopathy, nephropathy) and macrovascular (CVD, stroke) complications. Per endocrinology practices aligned with ICMR, RSSDI, and National Programme for Prevention and Control of Cancer, Diabetes, CVD and Stroke guidelines, the test employs spectrophotometry/immunoassay for fasting glucose, HbA1c, insulin, and C-peptide over 1-2 days with high accuracy, valuable for diagnosing diabetes/prediabetes (HbA1c ≥6.5 percent diagnostic) and assessing insulin resistance/secretion. This diagnostic falls under metabolic screening and targets adults with risk factors (obesity, family history, gestational diabetes history), addressing accurate detection to guide diet, exercise, metformin, or insulin. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early diabetes profiling and reducing complication burden. Its plasma-based approach ensures reliable glucose/HbA1c measurement.
Other Names: Sugar Check Pnl.
FDA Status: FDA approved, CLIA certified for biochemistry/immunology, compliant with 2025 standards.
Historical Milestone: HbA1c + fasting glucose standard in diabetes diagnosis; in India, core of RSSDI guidelines.
Purpose: The test assesses 4 parameters including fasting glucose to guide diabetes screening, detect hyperglycemia/insulin issues, inform lifestyle/medication.
Test Parameters: 1. Fasting Glucose, 2. HbA1c, 3. Insulin, 4. C-Peptide.
Pretest Condition: Fasting 10-12 hours required; patients should be at-risk adults.
Specimen: 3 mL plasma in NaF tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve glucose integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on family diabetes, obesity, symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected diabetes including complications, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using spectrophotometry/immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or non-fasting can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Elevated fasting glucose/HbA1c indicates diabetes/prediabetes; low C-peptide suggests insulin deficiency, necessitating specialist input.
Specialist Consultation: Endocrinologists or diabetologists should be consulted for management.
Additional Supporting Tests: OGTT, anti-GAD antibodies for confirmation.
Test Limitations: Fasting requirement critical; comprehensive approach required.
References: Indian Journal of Endocrinology 2024, Diabetes Studies India 2023.
